Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

In a world shaped by biotechnology, why are so few college students exposed to its possibilities early on in their education?

A recovery from this prolonged and painful market downturn will require a major attitude adjustment from biotech management ...

The company bought the rights to an experimental cancer drug for $1.3 billion, plus potential milestone payments of $4.8 ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Biotech is growing in North Carolina, and now one Triad college is stepping up to help train the workforce. Guilford Technical Community College is launching a ...

Bankrupt genetic testing company 23andMe has been sold to Regeneron Pharmaceuticals for $256 million. The deal includes ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Chicago’s life sciences market is the smallest of any major U.S. market by square footage yet has a vacancy rate of 43.3 ...

Silence is always an option. Except when it shouldn’t be. Like when the institution in your care is under siege. Like right ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...